title: Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis.
abstract: BACKGROUND
  Vildagliptin can be used in patients with type 2 diabetes mellitus and renal impairment. However, there have been few reports investigating the clinical effectiveness of vildagliptin in diabetic patients undergoing hemodialysis. No previous studies have evaluated the use of vildagliptin in patients undergoing peritoneal dialysis. The authors determined the usefulness of vildagliptin for treating type 2 diabetic patients receiving chronic dialysis, including peritoneal dialysis.
  
  
  METHODS
  A retrospective study of ten diabetic patients undergoing peritoneal dialysis and five diabetic patients undergoing hemodialysis who were treated with 50 mg/day of vildagliptin was performed. Clinical parameters were investigated for a period of 6 months starting from the vildagliptin therapy.
  
  
  RESULTS
  The hemoglobin A1c (HbA1c) levels were significantly reduced after baseline in both the peritoneal dialysis and hemodialysis groups, whereas the hemoglobin levels did not change during the follow-up period. The mean change in the HbA1c level (ΔHbA1c) was -0.6 ± 0.9% and -0.5 ± 0.7% among the patients undergoing peritoneal dialysis and hemodialysis, respectively. The glycated albumin (GA) levels were also significantly reduced compared with baseline in the peritoneal dialysis group, although the serum albumin levels did not change. The mean change in the GA level (ΔGA) was -3.4 ± 3.1% and -2.1 ± 2.5% among the patients undergoing peritoneal dialysis and hemodialysis, respectively. Stepwise multivariate analyses demonstrated the level of HbA1c at baseline to be significantly associated with the ΔHbA1c and that the level of GA at baseline was significantly associated with the ΔGA.
  
  
  CONCLUSIONS
  Vildagliptin exhibits effectiveness in patients with type 2 diabetes mellitus undergoing peritoneal dialysis or hemodialysis. The degree of improvement in the HbA1c and GA levels was dependent on these levels at baseline, similar to the findings of previous reports of subjects without end-stage kidney disease.
authors.affiliation: Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, 2-24-18, Higashikoiwa, Edogawa-ku, Tokyo, 133-0052, Japan, ito@edogawa.or.jp.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ito
authors.forename: Mizuo
authors.initials: M
authors.lastname: Mifune
authors.forename: Eriko
authors.initials: E
authors.lastname: Matsuyama
authors.forename: Masahide
authors.initials: M
authors.lastname: Furusho
authors.forename: Takashi
authors.initials: T
authors.lastname: Omoto
authors.forename: Masahiro
authors.initials: M
authors.lastname: Shinozaki
authors.forename: Shinya
authors.initials: S
authors.lastname: Nishio
authors.forename: Shinichi
authors.initials: S
authors.lastname: Antoku
authors.forename: Mariko
authors.initials: M
authors.lastname: Abe
authors.forename: Michiko
authors.initials: M
authors.lastname: Togane
authors.forename: Shoji
authors.initials: S
authors.lastname: Koga
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Sanaka